IMPOSITION of further restrictions to curb the spread of Covid-19 in the UK could put Caffe Nero’s future in doubt, the company’s top officials said.
Caffe Nero’s directors including founder Gerry Ford said a fresh wave of temporary closures and a legal challenge by landlords to restructuring of the business cast “material uncertainties” over its future, The Telegraph reported.
Its landlords challenged proposals to renegotiate rents after knowing that the billionaire Issa brothers made an eleventh-hour bid to take control of the company last November.
Caffe Nero’s auditors, EY, has also raised concerns over the company’s future due to uncertainty around the outcome of the restructuring and when trading would return to pre-pandemic levels.
The chain’s top executives remained worried about the possibility of a third wave of coronavirus, and the impact it would have on trade due to subsequent lockdown. In case of another lockdown, the company would find it difficult to pay off its £390 million of debt, they said.
Health secretary Matt Hancock said recently that the government is "absolutely open" to delaying the final lifting of England's Covid lockdown on June 21, if necessary.
The Issa brothers, who acquired Asda for £6.8 billion earlier this year, have bought £140m of Caffe Nero’s debts, putting them in a strong position to seize control of the business, if the chain defaults on its debt.
Meanwhile, the chain had just managed to meet the May 31 deadline to file its annual accounts and pledged to meet all of its banking covenants.
“As is the case for all other retail and hospitality businesses, we certainly hope the Government will not impose additional lockdowns as that would create further uncertainty,” a Caffe Nero spokesman said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.